McKesson signed a definitive agreement to acquire Precision Medicine Group for about $2.25 billion, aiming to deepen its oncology and clinical research services. The deal, structured as an all-cash transaction and subject to regulatory approvals, is designed to expand capabilities spanning biomarker intelligence, lab services, global clinical research organization (CRO) operations, and market access consulting. For biotech and pharma sponsors, the added footprint could mean tighter coordination from early development through commercialization and patient delivery—particularly for oncology programs where biomarkers and complex trial execution are central. Precision Medicine Group is expected to report within McKesson’s Oncology & Multispecialty segment. The transaction also underscores continued consolidation among services providers that support clinical trial execution and commercialization workflows, as biopharma places growing emphasis on evidence generation and operational scalability.